Industry News
Pharmaceutical Industry News
After beating AstraZeneca’s…
After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa has pulled further ahead.
Supreme Group said the deal…
Supreme Group said the deal deepens its expertise in rare disease and pharma and expands the creative and omnichannel solutions it can deliver.
Raising awareness of medical…
Raising awareness of medical products and services is a marathon, not a sprint, and Babson Diagnostics has therefore selected a star with plenty of stamina for a long-term partnership.
President Donald Trump has doubled…
President Donald Trump has doubled down on his plan to assess tariffs on imported pharmaceutical products, saying they will eventually reach 250%. The new figure comes a month after Trump reiterated his plan to tax
What Is Cardiac Amyloidosis?
A quiet revolution in care is helping patients with cardiac amyloidosis, a form of heart failure that long stumped doctors.
As investors and industry watchers…
As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing reform under the Trump administration, Pfizer CEO Albert Bourla, Ph.D.—who has frequently touted his strong relationship with the
In July, spending on TV ads for…
In July, spending on TV ads for prescription drugs reached a low not seen since this time last year.
Currax Pharmaceuticals is taking…
Currax Pharmaceuticals is taking its direct-to-consumer push national and partnering with patients to pitch its obesity treatment as a more affordable option than GLP-1 drugs.
Competition is coming for…
Competition is coming for BioMarin’s potential blockbuster Voxzogo, but the California biotech may be able to answer with a longer-acting version of the C-type natriuretic peptide (CNP), which treats a form of dwarfism in children
After talking with the FDA, Vertex…
After talking with the FDA, Vertex does not believe the regulator is amenable to a broad label for its non-opioid pain drug Journavx in peripheral polyneuropathy, a form of chronic pain caused by nerve damage.
More than 4 years after its first…
More than 4 years after its first FDA approval, Y-mAbs Therapeutics is moving to sell itself to SERB Pharmaceuticals.
Novo Nordisk underestimated the…
Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for its GLP-1 diabetes and obesity drugs Ozempic and Wegovy, according to an investor lawsuit.
Switzerland Rushes to Give Trump ‘More Attractive’ Offer to Cut Tariffs
The Swiss government said it had “no indication” the country would be hit with a 39 percent tariff, which is set to take effect this week.
Top medical groups that have…
Top medical groups that have historically helped the federal government establish vaccine recommendations have been pushed out of key vaccine work groups.
CDMO Thermo Fisher is laying off…
CDMO Thermo Fisher is laying off roughly 85 employees across its locations at Newton Drive and Van Allen Way in Carlsbad, according to a notice filed with the state of California. The company previously conducted
While the JAK inhibitor market for…
While the JAK inhibitor market for alopecia areata has grown increasingly crowded in recent years, Rinvoq’s clinical performance in the disease could earn AbbVie a prominent seat at the table. After 24 weeks of treatment,
In his first public appearance as…
In his first public appearance as Incyte’s CEO, Bill Meury outlined his priorities for the company, including taking a “fresh look” at the business across R&D, operating expenses and capital allocation.
As Eli Lilly rolls ahead with a…
As Eli Lilly rolls ahead with a $27 billion investment to prop up four new manufacturing facilities in the U.S, the company is moving to offload another plant with a checkered past.
A Cancer Patient Chose Assisted Death. That Wasn’t the Last Hard Choice.
Tatiana Andia knew Colombia would permit her a medically assisted death. She took her country with her on the journey to dying.
The changes come after a public…
The changes come after a public advisory committee meeting in May, which reviewed data from two large observational studies showing serious risks for patients who use opioids over a long time.